{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:51:20Z","timestamp":1794639080895,"version":"4.9.1"},"reference-count":262,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002651","name":"Barth Syndrome Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002651","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL139708\\u201302"],"award-info":[{"award-number":["R01 HL139708\\u201302"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG066653"],"award-info":[{"award-number":["R01AG066653"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG078702"],"award-info":[{"award-number":["R01AG078702"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA266004"],"award-info":[{"award-number":["R01CA266004"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA288696"],"award-info":[{"award-number":["R01 CA288696"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R33 NS111081"],"award-info":[{"award-number":["R33 NS111081"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35 NS116824"],"award-info":[{"award-number":["R35 NS116824"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01-NS116752\\u201301A1"],"award-info":[{"award-number":["U01-NS116752\\u201301A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002108","name":"Friedreich's Ataxia Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009358","name":"Duchenne Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009358","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.neurot.2024.e00446","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T23:39:05Z","timestamp":1726270745000},"page":"e00446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Neurological glycogen storage diseases and emerging therapeutics"],"prefix":"10.1016","volume":"21","author":[{"given":"Matthieu","family":"Colpaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine J.","family":"Donohue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha T.","family":"Pires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon C.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Vander Kooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Gentry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2024.e00446_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1566524024605761","article-title":"Glycogen and its metabolism","volume":"2","author":"Roach","year":"2002","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib2","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1042\/BCJ20170558","article-title":"Structural basis of glycogen metabolism in bacteria","volume":"476","author":"Cifuente","year":"2019","journal-title":"Biochem J"},{"key":"10.1016\/j.neurot.2024.e00446_bib3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/PL00006249","article-title":"How did glycogen structure evolve to satisfy the requirement for rapid mobilization of glucose? A problem of physical constraints in structure building","volume":"45","author":"Mel\u00e9ndez","year":"1997","journal-title":"J\u00a0Mol Evol"},{"key":"10.1016\/j.neurot.2024.e00446_bib4","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1042\/BJ20111416","article-title":"Glycogen and its metabolism: some new developments and old themes","volume":"441","author":"Roach","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.neurot.2024.e00446_bib5","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.1074\/jbc.R117.802843","article-title":"The dynamic life of the glycogen granule","volume":"293","author":"Prats","year":"2018","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.neurot.2024.e00446_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-3-030-27480-1_2","article-title":"Brain glycogen structure and its associated proteins: past, present and future","volume":"23","author":"Brewer","year":"2019","journal-title":"Adv Neurobiol"},{"key":"10.1016\/j.neurot.2024.e00446_bib7","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1530\/JOE-18-0120","article-title":"Biochemical and clinical aspects of glycogen storage diseases","volume":"238","author":"Ellingwood","year":"2018","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.neurot.2024.e00446_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41572-023-00456-z","article-title":"Glycogen storage diseases","volume":"9","author":"Hannah","year":"2023","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.neurot.2024.e00446_bib9","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.3748\/wjg.v29.i25.3932","article-title":"Glycogen storage diseases: an update","volume":"29","author":"G\u00fcm\u00fc\u015f","year":"2023","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.neurot.2024.e00446_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-3-030-27480-1_3","article-title":"Structure and regulation of glycogen synthase in the brain","volume":"23","author":"Pederson","year":"2019","journal-title":"Adv Neurobiol"},{"key":"10.1016\/j.neurot.2024.e00446_bib11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ymgme.2005.10.006","article-title":"Hepatic glycogen synthase deficiency: an infrequently recognized cause of ketotic hypoglycemia","volume":"87","author":"Weinstein","year":"2006","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib12","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa066691","article-title":"Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0","volume":"357","author":"Kollberg","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib13","doi-asserted-by":"crossref","first-page":"116260","DOI":"10.1016\/j.carbpol.2020.116260","article-title":"Polyglucosan body structure in Lafora disease","volume":"240","author":"Brewer","year":"2020","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.neurot.2024.e00446_bib14","series-title":"GeneReviews\u00ae [internet]","article-title":"Glycogen storage disease type IV","author":"Magoulas","year":"2013"},{"key":"10.1016\/j.neurot.2024.e00446_bib15","unstructured":"Akman HO, Lossos A, Kakhlon O. GBE1 adult polyglucosan body disease. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, et al., editors. GeneReviews\u00ae [internet]. Seattle (WA): University of Washington, Seattle; 2009 [cited 2024 Mar 11]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK5300\/."},{"key":"10.1016\/j.neurot.2024.e00446_bib16","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12325","article-title":"GBE1-related disorders: adult polyglucosan body disease and its neuromuscular phenotypes","volume":"44","author":"Souza","year":"2021","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.neurot.2024.e00446_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1432-1033.1991.tb16225.x","article-title":"The discovery of glycogenin and the priming mechanism for glycogen biogenesis","volume":"200","author":"Smythe","year":"1991","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.neurot.2024.e00446_bib18","doi-asserted-by":"crossref","first-page":"14687","DOI":"10.1016\/S0021-9258(18)82388-2","article-title":"Characterization of rabbit skeletal muscle glycogenin. Tyrosine 194 is essential for function","volume":"268","author":"Cao","year":"1993","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.neurot.2024.e00446_bib19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cmet.2017.06.008","article-title":"Lack of glycogenin causes glycogen accumulation and muscle function impairment","volume":"26","author":"Testoni","year":"2017","journal-title":"Cell Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ana.24284","article-title":"A\u00a0new muscle glycogen storage disease associated with glycogenin-1 deficiency","volume":"76","author":"Malfatti","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00446_bib21","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.3390\/ijms20235919","article-title":"McArdle disease: new insights into its underlying molecular mechanisms","volume":"20","author":"Llavero","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurot.2024.e00446_bib22","series-title":"GeneReviews\u00ae [internet]","article-title":"Glycogen storage disease type VI","author":"Labrador","year":"2009"},{"key":"10.1016\/j.neurot.2024.e00446_bib23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13023-022-02387-6","article-title":"Glycogen storage diseases with liver involvement: a literature review of GSD type 0, IV, VI, IX and XI","volume":"17","author":"Massese","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.neurot.2024.e00446_bib24","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/GIM.0b013e3181e655b6","article-title":"Glycogen storage disease type III diagnosis and management guidelines","volume":"12","author":"Kishnani","year":"2010","journal-title":"Genet Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib25","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/s41467-023-36484-2","article-title":"Sugar transporter Slc37a2 regulates bone metabolism in mice via a tubular lysosomal network in osteoclasts","volume":"14","author":"Ng","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2024.e00446_bib26","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.tem.2023.07.008","article-title":"Lysosomal glucose sensing and glycophagy in metabolism","volume":"34","author":"Mancini","year":"2023","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib27","doi-asserted-by":"crossref","first-page":"102093","DOI":"10.1016\/j.jbc.2022.102093","article-title":"Glycogen-autophagy: molecular machinery and cellular mechanisms of glycophagy","volume":"298","author":"Koutsifeli","year":"2022","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.neurot.2024.e00446_bib28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.mam.2015.08.003","article-title":"Glycogen phosphorylation and lafora disease","volume":"46","author":"Roach","year":"2015","journal-title":"Mol Aspect Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib29","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1074\/jbc.R117.803064","article-title":"Lafora disease offers a unique window into neuronal glycogen metabolism","volume":"293","author":"Gentry","year":"2018","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.neurot.2024.e00446_bib30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.neurol.2021.06.006","article-title":"Lafora disease: current biology and therapeutic approaches","volume":"178","author":"Mitra","year":"2022","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurot.2024.e00446_bib31","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/jnc.15926","article-title":"The multifaceted roles of the brain glycogen","volume":"168","author":"Markussen","year":"2023","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.neurot.2024.e00446_bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ajmg.c.31323","article-title":"Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: long-term follow-up","volume":"160C","author":"Spiridigliozzi","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.neurot.2024.e00446_bib33","doi-asserted-by":"crossref","first-page":"108119","DOI":"10.1016\/j.ymgme.2023.108119","article-title":"Severe CNS involvement in a subset of long-term treated children with infantile-onset Pompe disease","volume":"141","author":"Kenney-Jung","year":"2024","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.21037\/atm.2019.04.49","article-title":"An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond","volume":"7","author":"Korlimarla","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib35","first-page":"611","article-title":"[The glucose consumption of the brain & its dependence on the liver]","volume":"196","author":"Erbsloh","year":"1958","journal-title":"Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr"},{"key":"10.1016\/j.neurot.2024.e00446_bib36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1471-4159.2004.02421.x","article-title":"Brain glycogen re-awakened","volume":"89","author":"Brown","year":"2004","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.neurot.2024.e00446_bib37","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/jcbfm.2012.35","article-title":"Updated energy budgets for neural computation in the neocortex and cerebellum","volume":"32","author":"Howarth","year":"2012","journal-title":"J\u00a0Cerebr Blood Flow Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib38","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/jnr.24374","article-title":"Neurons rely on glucose rather than astrocytic lactate during stimulation","volume":"97","author":"D\u00edaz-Garc\u00eda","year":"2019","journal-title":"J\u00a0Neurosci Res"},{"key":"10.1016\/j.neurot.2024.e00446_bib39","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1152\/physrev.00062.2017","article-title":"Brain glucose metabolism: integration of energetics with function","volume":"99","author":"Dienel","year":"2019","journal-title":"Physiol Rev"},{"key":"10.1016\/j.neurot.2024.e00446_bib40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000508054","article-title":"Brain fuel utilization in the developing brain","volume":"75","author":"Steiner","year":"2020","journal-title":"Ann Nutr Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib41","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/glia.20440","article-title":"Hypoglycemia, brain energetics, and hypoglycemic neuronal death","volume":"55","author":"Suh","year":"2007","journal-title":"Glia"},{"key":"10.1016\/j.neurot.2024.e00446_bib42","doi-asserted-by":"crossref","first-page":"634305","DOI":"10.3389\/fendo.2021.634305","article-title":"Neonatal hypoglycemia and brain vulnerability","volume":"12","author":"De Angelis","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.neurot.2024.e00446_bib43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fnene.2012.00003","article-title":"Brain glycogen\u2014new perspectives on its metabolic function and regulation at the subcellular level","volume":"4","author":"Obel","year":"2012","journal-title":"Front Neuroenergetics"},{"key":"10.1016\/j.neurot.2024.e00446_bib44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/978-3-030-27480-1_12","article-title":"Role of brain glycogen during ischemia, aging and cell-to-cell interactions","volume":"23","author":"Bastian","year":"2019","journal-title":"Adv Neurobiol"},{"key":"10.1016\/j.neurot.2024.e00446_bib45","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-3-030-27480-1_8","article-title":"Glycogenolysis in cerebral cortex during sensory stimulation, acute hypoglycemia, and exercise: impact on astrocytic energetics, aerobic glycolysis, and astrocyte-neuron interactions","volume":"23","author":"Dienel","year":"2019","journal-title":"Adv Neurobiol."},{"key":"10.1016\/j.neurot.2024.e00446_bib46","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12974-021-02284-y","article-title":"Astrocytic A1\/A2 paradigm participates in glycogen mobilization mediated neuroprotection on reperfusion injury after ischemic stroke","volume":"18","author":"Guo","year":"2021","journal-title":"J\u00a0Neuroinflammation"},{"key":"10.1016\/j.neurot.2024.e00446_bib47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-3-030-27480-1_7","article-title":"Metabolism of glycogen in brain white matter","volume":"23","author":"Brown","year":"2019","journal-title":"Adv Neurobiol"},{"key":"10.1016\/j.neurot.2024.e00446_bib48","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-3-030-27480-1_6","article-title":"Technical and comparative aspects of brain glycogen metabolism","volume":"23","author":"Wu","year":"2019","journal-title":"Adv Neurobiol"},{"issue":"Suppl 1","key":"10.1016\/j.neurot.2024.e00446_bib49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1471-4159.2009.05915.x","article-title":"Functional significance of brain glycogen in sustaining glutamatergic neurotransmission","volume":"109","author":"Sickmann","year":"2009","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.neurot.2024.e00446_bib50","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.neuint.2011.12.019","article-title":"Brain glycogen and its role in supporting glutamate and GABA homeostasis in a type 2 diabetes rat model","volume":"60","author":"Sickmann","year":"2012","journal-title":"Neurochem Int"},{"key":"10.1016\/j.neurot.2024.e00446_bib51","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.neuron.2012.08.032","article-title":"Metabolic communication between astrocytes and neurons via bicarbonate-responsive soluble adenylyl cyclase","volume":"75","author":"Choi","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2024.e00446_bib52","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/978-3-030-27480-1_9","article-title":"State-dependent changes in brain glycogen metabolism","volume":"23","author":"DiNuzzo","year":"2019","journal-title":"Adv Neurobiol"},{"key":"10.1016\/j.neurot.2024.e00446_bib53","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cmet.2011.08.016","article-title":"Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation","volume":"14","author":"B\u00e9langer","year":"2011","journal-title":"Cell Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib54","doi-asserted-by":"crossref","first-page":"10625","DOI":"10.1073\/pnas.91.22.10625","article-title":"Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization","volume":"91","author":"Pellerin","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.neurot.2024.e00446_bib55","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.neuron.2015.03.035","article-title":"A\u00a0cellular perspective on brain energy metabolism and functional imaging","volume":"86","author":"Magistretti","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2024.e00446_bib56","doi-asserted-by":"crossref","first-page":"114173","DOI":"10.1016\/j.expneurol.2022.114173","article-title":"Aging astrocytes metabolically support aging axon function by proficiently regulating astrocyte-neuron lactate shuttle","volume":"357","author":"Bastian","year":"2022","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurot.2024.e00446_bib57","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1002\/jnr.24015","article-title":"Lack of appropriate stoichiometry: strong evidence against an energetically important astrocyte-neuron lactate shuttle in brain","volume":"95","author":"Dienel","year":"2017","journal-title":"J\u00a0Neurosci Res"},{"key":"10.1016\/j.neurot.2024.e00446_bib58","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/jnc.16004","article-title":"The dentate gyrus differentially metabolizes glucose and alternative fuels during rest and stimulation","volume":"168","author":"York","year":"2024","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.neurot.2024.e00446_bib59","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1177\/0271678X211064399","article-title":"Glucose sparing by glycogenolysis (GSG) determines the relationship between brain metabolism and neurotransmission","volume":"42","author":"Rothman","year":"2022","journal-title":"J\u00a0Cerebr Blood Flow Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib60","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-3-030-27480-1_5","article-title":"Regional distribution of glycogen in the mouse brain visualized by immunohistochemistry","volume":"23","author":"Oe","year":"2019","journal-title":"Adv Neurobiol"},{"key":"10.1016\/j.neurot.2024.e00446_bib61","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/jnr.24386","article-title":"Glycogen distribution in mouse hippocampus","volume":"97","author":"Hirase","year":"2019","journal-title":"J\u00a0Neurosci Res"},{"key":"10.1016\/j.neurot.2024.e00446_bib62","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/jcbfm.2014.33","article-title":"Neurons have an active glycogen metabolism that contributes to tolerance to hypoxia","volume":"34","author":"Saez","year":"2014","journal-title":"J\u00a0Cerebr Blood Flow Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib63","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/glia.23020","article-title":"Glycogen distribution in the microwave-fixed mouse brain reveals heterogeneous astrocytic patterns","volume":"64","author":"Oe","year":"2016","journal-title":"Glia"},{"key":"10.1016\/j.neurot.2024.e00446_bib64","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41419-017-0190-5","article-title":"Glycogen synthase protects neurons from cytotoxicity of mutant huntingtin by enhancing the autophagy flux","volume":"9","author":"Rai","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.neurot.2024.e00446_bib65","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12974-022-02595-8","article-title":"Ultrastructural characterization of dark microglia during aging in a mouse model of Alzheimer\u2019s disease pathology and in human post-mortem brain samples","volume":"19","author":"St-Pierre","year":"2022","journal-title":"J\u00a0Neuroinflammation"},{"key":"10.1016\/j.neurot.2024.e00446_bib66","first-page":"1","article-title":"Glycogen from spinal astrocytes dials up the pain","author":"D\u00edaz-Garc\u00eda","year":"2024","journal-title":"Nat Metab"},{"key":"10.1016\/j.neurot.2024.e00446_bib67","first-page":"1","article-title":"Neuron\u2013astrocyte metabolic coupling facilitates spinal plasticity and maintenance of inflammatory pain","author":"Marty-Lombardi","year":"2024","journal-title":"Nat Metab"},{"key":"10.1016\/j.neurot.2024.e00446_bib68","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/cercor\/bhz226","article-title":"Ultrastructural evidence for a role of astrocytes and glycogen-derived lactate in learning-dependent synaptic stabilization","volume":"30","author":"Vezzoli","year":"2020","journal-title":"Cerebr Cortex"},{"key":"10.1016\/j.neurot.2024.e00446_bib69","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1146\/annurev-neuro-091922-031205","article-title":"Astrocyte endfeet in brain function and pathology: open questions","volume":"46","author":"D\u00edaz-Castro","year":"2023","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.neurot.2024.e00446_bib70","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.cmet.2021.05.003","article-title":"Brain glycogen serves as a critical glucosamine cache required for protein glycosylation","volume":"33","author":"Sun","year":"2021","journal-title":"Cell Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib71","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.tem.2021.09.006","article-title":"Emerging roles of N-linked glycosylation in brain physiology and disorders","volume":"32","author":"Conroy","year":"2021","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib72","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/glia.20377","article-title":"Inhibition of glycogenolysis in astrocytes interrupts memory consolidation in young chickens","volume":"54","author":"Gibbs","year":"2006","journal-title":"Glia"},{"key":"10.1016\/j.neurot.2024.e00446_bib73","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/jcbfm.2012.200","article-title":"Impairment in long-term memory formation and learning-dependent synaptic plasticity in mice lacking glycogen synthase in the brain","volume":"33","author":"Duran","year":"2013","journal-title":"J\u00a0Cerebr Blood Flow Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib74","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3389\/fncel.2019.00374","article-title":"Lack of neuronal glycogen impairs memory formation and learning-dependent synaptic plasticity in mice","volume":"13","author":"Duran","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.neurot.2024.e00446_bib75","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/s41591-024-02960-5","article-title":"Dynamics of cognitive variability with age and its genetic underpinning in NIHR BioResource Genes and Cognition cohort participants","volume":"30","author":"Rahman","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib76","first-page":"227","article-title":"Familial dementia due to adult polyglucosan body disease","volume":"16","author":"Bigio","year":"1997","journal-title":"Clin Neuropathol"},{"key":"10.1016\/j.neurot.2024.e00446_bib77","doi-asserted-by":"crossref","first-page":"290","DOI":"10.21037\/atm.2019.05.56","article-title":"Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy","volume":"7","author":"Byrne","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib78","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10545-014-9789-1","article-title":"Cognitive profile of patients with glycogen storage disease type III: a clinical description of seven cases","volume":"38","author":"Michon","year":"2015","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.neurot.2024.e00446_bib79","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12891-020-03884-0","article-title":"Polyglucosan body myopathy 1 may cause cognitive impairment: a case report from China","volume":"22","author":"Chen","year":"2021","journal-title":"BMC Muscoskel Disord"},{"key":"10.1016\/j.neurot.2024.e00446_bib80","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.pediatrneurol.2015.08.001","article-title":"Glucose transporter type I deficiency (G1D) at 25 (1990\u20132015): presumptions, facts and the lives of persons with this rare disease","volume":"53","author":"Pascual","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.neurot.2024.e00446_bib81","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/2470","article-title":"Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy","volume":"20","author":"Minassian","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurot.2024.e00446_bib82","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/hmg\/8.2.345","article-title":"A\u00a0novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2)","volume":"8","author":"Serratosa","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00446_bib83","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/ng1238","article-title":"Mutations in NHLRC1 cause progressive myoclonus epilepsy","volume":"35","author":"Chan","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurot.2024.e00446_bib84","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1111\/epi.12806","article-title":"Mild Lafora disease: clinical, neurophysiologic, and genetic findings","volume":"55","author":"Ferlazzo","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurot.2024.e00446_bib85","doi-asserted-by":"crossref","first-page":"103276","DOI":"10.1016\/j.isci.2021.103276","article-title":"An empirical pipeline for personalized diagnosis of Lafora disease mutations","volume":"24","author":"Brewer","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.neurot.2024.e00446_bib86","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/hmg\/ddy044","article-title":"Astrocytes: new players in progressive myoclonus epilepsy of Lafora type","volume":"27","author":"Rubio-Villena","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00446_bib87","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.3390\/biomedicines10123103","article-title":"Glial contributions to lafora disease: a systematic review","volume":"10","author":"Della Vecchia","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.neurot.2024.e00446_bib88","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3390\/cells12050722","article-title":"Role of astrocytes in the pathophysiology of lafora disease and other glycogen storage disorders","volume":"12","author":"Duran","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.neurot.2024.e00446_bib89","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00401-024-02698-x","article-title":"Myofiber-type-dependent \u2018boulder\u2019 or \u2018multitudinous pebble\u2019 formations across distinct amylopectinoses","volume":"147","author":"Mitra","year":"2024","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2024.e00446_bib90","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/hmg\/ddr590","article-title":"Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy","volume":"21","author":"Criado","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00446_bib91","doi-asserted-by":"crossref","first-page":"25372","DOI":"10.1074\/jbc.M110.148668","article-title":"Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin","volume":"285","author":"DePaoli-Roach","year":"2010","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.neurot.2024.e00446_bib92","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/hmg\/11.11.1251","article-title":"Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice","volume":"11","author":"Ganesh","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00446_bib93","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ana.22156","article-title":"Glycogen hyperphosphorylation underlies lafora body formation","volume":"68","author":"Turnbull","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00446_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002037","article-title":"PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease","volume":"7","author":"Turnbull","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1016\/j.neurot.2024.e00446_bib95","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ana.24104","article-title":"PTG protein depletion rescues malin-deficient Lafora disease in mouse","volume":"75","author":"Turnbull","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00446_bib96","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/hmg\/ddu024","article-title":"Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease","volume":"23","author":"Duran","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00446_bib97","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1007\/s12035-020-02055-5","article-title":"Lack of astrocytic glycogen alters synaptic plasticity but not seizure susceptibility","volume":"57","author":"Duran","year":"2020","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.neurot.2024.e00446_bib98","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1093\/brain\/awab110","article-title":"Astrocytic glycogen accumulation drives the pathophysiology of neurodegeneration in Lafora disease","volume":"144","author":"Duran","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2024.e00446_bib99","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1093\/hmg\/ddx357","article-title":"Suppression of leptin signaling reduces polyglucosan inclusions and seizure susceptibility in a mouse model for Lafora disease","volume":"26","author":"Rai","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00446_bib100","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1007\/s12035-020-02170-3","article-title":"Trehalose ameliorates seizure susceptibility in lafora disease mouse models by suppressing neuroinflammation and endoplasmic reticulum stress","volume":"58","author":"Sinha","year":"2021","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.neurot.2024.e00446_bib101","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1684\/epd.2016.0842","article-title":"Lafora disease","volume":"18","author":"Turnbull","year":"2016","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.neurot.2024.e00446_bib102","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41582-018-0057-0","article-title":"Lafora disease \u2014 from pathogenesis to treatment strategies","volume":"14","author":"Nitschke","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurot.2024.e00446_bib103","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13023-023-02880-6","article-title":"Prognostic value of pathogenic variants in Lafora Disease: systematic review and meta-analysis of patient-level data","volume":"18","author":"Pondrelli","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.neurot.2024.e00446_bib104","first-page":"165","article-title":"Immunohistochemical and ultrastructural changes in the brain in probable adult glycogenosis type IV: adult polyglucosan body disease","volume":"46","author":"Wierzba-Bobrowicz","year":"2008","journal-title":"Folia Neuropathol"},{"key":"10.1016\/j.neurot.2024.e00446_bib105","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1093\/hmg\/ddv385","article-title":"A\u00a0novel mouse model that recapitulates adult-onset glycogenosis type 4","volume":"24","author":"Orhan Akman","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00446_bib106","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ana.23598","article-title":"Adult polyglucosan body disease: natural history and key magnetic resonance imaging findings","volume":"72","author":"Mochel","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00446_bib107","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s002340000425","article-title":"Extensive white-matter changes in case of adult polyglucosan body disease","volume":"43","author":"Berkhoff","year":"2001","journal-title":"Neuroradiology"},{"key":"10.1016\/j.neurot.2024.e00446_bib108","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jns.2012.10.015","article-title":"Acute but transient neurological deterioration revealing adult polyglucosan body disease","volume":"324","author":"Billot","year":"2013","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.neurot.2024.e00446_bib109","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jocn.2006.03.001","article-title":"Stable neuropsychological deficits in adult polyglucosan body disease","volume":"14","author":"Savage","year":"2007","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.neurot.2024.e00446_bib110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamaneurol.2013.4888","article-title":"Branching enzyme deficiency: expanding the clinical spectrum","volume":"71","author":"Paradas","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2024.e00446_bib111","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.gene.2012.12.065","article-title":"Abnormal glycogen in astrocytes is sufficient to cause adult polyglucosan body disease","volume":"515","author":"Dainese","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.neurot.2024.e00446_bib112","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/mus.25017","article-title":"Polyglucosan bodies in intramuscular nerve branches are a poor predictor of GBE1 mutation and adult polyglucosan body disease","volume":"53","author":"Furtado","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neurot.2024.e00446_bib113","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1002\/acn3.51211","article-title":"GYS1 or PPP1R3C deficiency rescues murine adult polyglucosan body disease","volume":"7","author":"Chown","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2024.e00446_bib114","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s13311-022-01218-7","article-title":"AAV-mediated artificial miRNA reduces pathogenic polyglucosan bodies and neuroinflammation in adult polyglucosan body and lafora disease mouse models","volume":"19","author":"Gumusgoz","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2024.e00446_bib115","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99694","article-title":"Guaiacol as a drug candidate for treating adult polyglucosan body disease","volume":"3","author":"Kakhlon","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.neurot.2024.e00446_bib116","article-title":"An analysis of Pompe newborn screening data: a new prevalence at birth, insight and discussion","volume":"11","author":"Colburn","year":"2023","journal-title":"Front Pediatr"},{"key":"10.1016\/j.neurot.2024.e00446_bib117","first-page":"304","article-title":"Over idiopathische hypertrophie van het hart","volume":"76","author":"Pompe","year":"1932","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.neurot.2024.e00446_bib118","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bj0860011","article-title":"\u03b1-Glucosidase deficiency in generalized glycogen-storage disease (Pompe's disease)","volume":"86","author":"Hers","year":"1963","journal-title":"Biochem J"},{"key":"10.1016\/j.neurot.2024.e00446_bib119","first-page":"1","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.neurot.2024.e00446_bib120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/jimd.12560","article-title":"Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolism","volume":"46","author":"Canibano-Fraile","year":"2023","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.neurot.2024.e00446_bib121","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.nmd.2021.01.010","article-title":"251st ENMC international workshop: polyglucosan storage myopathies 13\u201315 December 2019, Hoofddorp, The Netherlands","volume":"31","author":"Lafor\u00eat","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.neurot.2024.e00446_bib122","first-page":"271","article-title":"Infantile-onset Pompe disease: diagnosis and management","volume":"117","author":"Bay","year":"2019","journal-title":"Arch Argent Pediatr"},{"key":"10.1016\/j.neurot.2024.e00446_bib123","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13052-022-01379-3","article-title":"Infantile Pompe disease with intrauterine onset: a case report and literature review","volume":"48","author":"Xi","year":"2022","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.neurot.2024.e00446_bib124","doi-asserted-by":"crossref","first-page":"e9186","DOI":"10.1097\/MD.0000000000009186","article-title":"Infantile-onset Pompe disease with neonatal debut","volume":"96","author":"Mart\u00ednez","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.neurot.2024.e00446_bib125","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3390\/biom10091339","article-title":"Pompe disease: new developments in an old lysosomal storage disorder","volume":"10","author":"Meena","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.neurot.2024.e00446_bib126","doi-asserted-by":"crossref","first-page":"15856","DOI":"10.18632\/aging.103794","article-title":"Pompe disease: pathogenesis, molecular genetics and diagnosis","volume":"12","author":"Taverna","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.neurot.2024.e00446_bib127","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3390\/biom13091279","article-title":"A\u00a0comprehensive update on late-onset Pompe disease","volume":"13","author":"Labella","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.neurot.2024.e00446_bib128","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ymgme.2013.06.023","article-title":"Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function","volume":"110","author":"Gaeta","year":"2013","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.resp.2015.11.013","article-title":"Altered activation of the diaphragm in late-onset Pompe disease","volume":"222","author":"Smith","year":"2016","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1016\/j.neurot.2024.e00446_bib130","doi-asserted-by":"crossref","first-page":"19006","DOI":"10.1038\/s41598-019-54314-8","article-title":"Dynamic respiratory muscle function in late-onset Pompe disease","volume":"9","author":"Smith","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2024.e00446_bib131","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1152\/jn.00190.2021","article-title":"Case Studies in Neuroscience: neuropathology and diaphragm dysfunction in ventilatory failure from late-onset Pompe disease","volume":"126","author":"Fuller","year":"2021","journal-title":"J\u00a0Neurophysiol"},{"key":"10.1016\/j.neurot.2024.e00446_bib132","doi-asserted-by":"crossref","first-page":"284","DOI":"10.21037\/atm.2019.07.24","article-title":"Multisystem late onset Pompe disease (LOPD): an update on clinical aspects","volume":"7","author":"Toscano","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib133","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib134","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41431-020-00752-2","article-title":"Enzymatic diagnosis of Pompe disease: lessons from 28 years of experience","volume":"29","author":"Ni\u00f1o","year":"2021","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.neurot.2024.e00446_bib135","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11940-022-00736-1","article-title":"Pompe disease: a clinical, diagnostic, and therapeutic overview","volume":"24","author":"Stevens","year":"2022","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.neurot.2024.e00446_bib136","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/jnnp.26.5.422","article-title":"Neuropathological and neurochemical aspects of generalized glycogen storage disease","volume":"26","author":"Crome","year":"1963","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2024.e00446_bib137","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/01.CIR.23.2.261","article-title":"Glycogen-storage disease","volume":"23","author":"Muller","year":"1961","journal-title":"Circulation"},{"key":"10.1016\/j.neurot.2024.e00446_bib138","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00005072-196501000-00008","article-title":"POMPE\u2019S disease (diffuse glycogenosis) with neuronal storage","volume":"24","author":"Mancall","year":"1965","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"key":"10.1016\/j.neurot.2024.e00446_bib139","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00005072-197107000-00008","article-title":"Nervous system in Pompe's disease. Ultrastructure and biochemistry","volume":"30","author":"Gambetti","year":"1971","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"key":"10.1016\/j.neurot.2024.e00446_bib140","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.1073\/pnas.0902534106","article-title":"Neural deficits contribute to respiratory insufficiency in Pompe disease","volume":"106","author":"DeRuisseau","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.neurot.2024.e00446_bib141","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.resp.2013.06.007","article-title":"The respiratory neuromuscular system in Pompe disease","volume":"189","author":"Fuller","year":"2013","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1016\/j.neurot.2024.e00446_bib142","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/jimd.12736","article-title":"Long term survival in patients with classic infantile Pompe disease reveals a spectrum with progressive brain abnormalities and changes in cognitive functioning","volume":"47","author":"van den Dorpel","year":"2024","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.neurot.2024.e00446_bib143","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.resp.2016.02.007","article-title":"Neuropathology in respiratory-related motoneurons in young Pompe (Gaa\u2212\/\u2212) mice","volume":"227","author":"Turner","year":"2016","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1016\/j.neurot.2024.e00446_bib144","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/cells10010008","article-title":"Modeling CNS involvement in Pompe disease using neural stem cells generated from patient-derived induced pluripotent stem cells","volume":"10","author":"Cheng","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.neurot.2024.e00446_bib145","first-page":"1730","article-title":"Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease","volume":"257","author":"Sacconi","year":"2010","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.neurot.2024.e00446_bib146","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ymgme.2012.07.024","article-title":"Auditory system involvement in late onset Pompe disease: a study of 20 Italian patients","volume":"107","author":"Musumeci","year":"2012","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib147","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s10545-013-9601-7","article-title":"The brain in late-onset glycogenosis II: a structural and functional MRI study","volume":"36","author":"Borroni","year":"2013","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.neurot.2024.e00446_bib148","doi-asserted-by":"crossref","first-page":"123021","DOI":"10.1016\/j.jns.2024.123021","article-title":"Diaphragm weakness in late-onset Pompe disease: a complex interplay between lower motor neuron and muscle fibre degeneration","volume":"460","author":"Oliveira Santos","year":"2024","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.neurot.2024.e00446_bib149","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00446_bib150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.gim.2022.10.005","article-title":"Evaluating brain white matter hyperintensity, IQ scores, and plasma neurofilament light chain concentration in early-treated patients with infantile-onset Pompe disease","volume":"25","author":"Hsu","year":"2023","journal-title":"Genet Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib151","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/dmcn.13740","article-title":"Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain","volume":"60","author":"Ebbink","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.neurot.2024.e00446_bib152","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ymgme.2017.10.005","article-title":"Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy","volume":"123","author":"McIntosh","year":"2018","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib153","first-page":"1662","article-title":"Diffusion tensor imaging of the brain in Pompe disease","volume":"270","author":"van den Dorpel","year":"2023","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.neurot.2024.e00446_bib154","doi-asserted-by":"crossref","first-page":"283","DOI":"10.21037\/atm.2019.04.70","article-title":"Long-term outcome and unmet needs in infantile-onset Pompe disease","volume":"7","author":"Hahn","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib155","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/mt.2013.282","article-title":"Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in Pompe mice","volume":"22","author":"ElMallah","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00446_bib156","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/mt.2013.96","article-title":"Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease","volume":"21","author":"Falk","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00446_bib157","doi-asserted-by":"crossref","first-page":"e1957","DOI":"10.1002\/mgg3.1957","article-title":"Classic infantile-onset Pompe disease with histopathological neurologic findings linked to a novel GAA gene 4 bp deletion: a case study","volume":"10","author":"Cer\u00f3n-Rodr\u00edguez","year":"2022","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib158","series-title":"GeneReviews\u00ae [internet]","article-title":"Pompe disease","author":"Leslie","year":"1993"},{"key":"10.1016\/j.neurot.2024.e00446_bib159","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.clinthera.2011.05.073","article-title":"Late onset Pompe disease under the mask of myoclonus epilepsy","volume":"33","author":"Sukhorukov","year":"2011","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.neurot.2024.e00446_bib160","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.ymgme.2021.11.170","article-title":"Seizures in infantile Pompe disease: expanding our understanding of the clinical spectrum","volume":"135","author":"Korlimarla","year":"2022","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib161","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.nmd.2022.03.008","article-title":"A\u00a0new phenotype of muscle glycogen synthase deficiency (GSD0B) characterized by an adult onset myopathy without cardiomyopathy","volume":"32","author":"Musumeci","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.neurot.2024.e00446_bib162","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ymgme.2009.07.012","article-title":"Identification of a novel mutation in GYS1 (muscle-specific glycogen synthase) resulting in sudden cardiac death, that is diagnosable from skin fibroblasts","volume":"98","author":"Cameron","year":"2009","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib163","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.nmd.2011.08.008","article-title":"Muscle glycogen storage disease 0 presenting recurrent syncope with weakness and myalgia","volume":"22","author":"Sukigara","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.neurot.2024.e00446_bib164","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10545-016-9932-2","article-title":"Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome","volume":"39","author":"Sentner","year":"2016","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"Suppl 1","key":"10.1016\/j.neurot.2024.e00446_bib165","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1007\/s10545-009-1088-x","article-title":"Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet","volume":"32","author":"Dagli","year":"2009","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.neurot.2024.e00446_bib166","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021109700","article-title":"HOIL-1 ubiquitin ligase activity targets unbranched glucosaccharides and is required to prevent polyglucosan accumulation","volume":"41","author":"Kelsall","year":"2022","journal-title":"EMBO J"},{"key":"10.1016\/j.neurot.2024.e00446_bib167","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/WCO.0000000000000484","article-title":"Update on new muscle glycogenosis","volume":"30","author":"Lafor\u00eat","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.neurot.2024.e00446_bib168","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/ncb1821","article-title":"Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation","volume":"11","author":"Tokunaga","year":"2009","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.neurot.2024.e00446_bib169","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1093\/brain\/awac017","article-title":"Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency","volume":"145","author":"Nitschke","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2024.e00446_bib170","doi-asserted-by":"crossref","first-page":"eabn2956","DOI":"10.1126\/scitranslmed.abn2956","article-title":"Metabolic modulation of synaptic failure and thalamocortical hypersynchronization with preserved consciousness in Glut1 deficiency","volume":"14","author":"Rajasekaran","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib171","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","article-title":"A\u00a0blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.neurot.2024.e00446_bib172","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","article-title":"Blood-brain barrier and delivery of protein and gene therapeutics to brain","volume":"11","author":"Pardridge","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.neurot.2024.e00446_bib173","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr Res"},{"key":"10.1016\/j.neurot.2024.e00446_bib174","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10545-011-9285-9","article-title":"Biotherapeutic target or sink: analysis of the macrophage mannose receptor tissue distribution in murine models of lysosomal storage diseases","volume":"34","author":"Zhang","year":"2011","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.neurot.2024.e00446_bib175","doi-asserted-by":"crossref","first-page":"291","DOI":"10.21037\/atm.2019.04.15","article-title":"Challenges in treating Pompe disease: an industry perspective","volume":"7","author":"Do","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib176","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13023-018-0771-0","article-title":"Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy","volume":"13","author":"Parini","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.neurot.2024.e00446_bib177","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s40265-021-01600-3","article-title":"Avalglucosidase alfa: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.neurot.2024.e00446_bib178","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2024.e00446_bib179","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","volume":"29","author":"Pena","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.neurot.2024.e00446_bib180","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00446_bib181","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125358","article-title":"Improved efficacy of a next-generation ERT in murine Pompe disease","volume":"4","author":"Xu","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.neurot.2024.e00446_bib182","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s40265-023-01886-5","article-title":"Cipaglucosidase alfa: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.neurot.2024.e00446_bib183","doi-asserted-by":"crossref","first-page":"35215","DOI":"10.1074\/jbc.M109.056184","article-title":"Cation-independent mannose 6-phosphate receptor: a composite of distinct phosphomannosyl binding sites","volume":"284","author":"Bohnsack","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.neurot.2024.e00446_bib184","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1021\/bc400365a","article-title":"Glycan structure determinants for cation-independent mannose 6-phosphate receptor binding and cellular uptake of a recombinant protein","volume":"24","author":"Zhou","year":"2013","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.neurot.2024.e00446_bib185","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2174\/1389450117666151209120139","article-title":"Delivery of therapeutic proteins: challenges and strategies","volume":"17","author":"Rehman","year":"2016","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.neurot.2024.e00446_bib186","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.molmed.2019.08.005","article-title":"Antibody-mediated enzyme therapeutics and applications in glycogen storage diseases","volume":"25","author":"Zhou","year":"2019","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib187","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.tips.2021.09.009","article-title":"Engineered antibody fusion proteins for targeted disease therapy","volume":"42","author":"Silver","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.neurot.2024.e00446_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114234","article-title":"Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins","volume":"184","author":"Pardridge","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.neurot.2024.e00446_bib189","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00109-017-1505-9","article-title":"Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease","volume":"95","author":"Yi","year":"2017","journal-title":"J\u00a0Mol Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib190","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1100\/tsw.2005.98","article-title":"Antibody mediated transduction of therapeutic proteins into living cells","volume":"5","author":"Hansen","year":"2005","journal-title":"Sci World J"},{"key":"10.1016\/j.neurot.2024.e00446_bib191","doi-asserted-by":"crossref","first-page":"20790","DOI":"10.1074\/jbc.C700090200","article-title":"Intranuclear protein transduction through a nucleoside salvage pathway","volume":"282","author":"Hansen","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.neurot.2024.e00446_bib192","doi-asserted-by":"crossref","first-page":"157ra142","DOI":"10.1126\/scitranslmed.3004385","article-title":"Targeting cancer with a lupus autoantibody","volume":"4","author":"Hansen","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib193","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1158\/1535-7163.MCT-12-0476-T","article-title":"A\u00a0cell-penetrating bispecific antibody for therapeutic regulation of intracellular targets","volume":"11","author":"Weisbart","year":"2012","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.neurot.2024.e00446_bib194","doi-asserted-by":"crossref","first-page":"12022","DOI":"10.1038\/srep12022","article-title":"DNA-dependent targeting of cell nuclei by a lupus autoantibody","volume":"5","author":"Weisbart","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2024.e00446_bib195","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.ymgme.2018.12.211","article-title":"Safety and efficacy of VAL-1221, a novel fusion protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease","volume":"126","author":"Kishnani","year":"2019","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib196","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood-brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurot.2024.e00446_bib197","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00446_bib198","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/164_2020_402","article-title":"Brain distribution of drugs: brain morphology, delivery routes, and species differences","volume":"273","author":"Bourasset","year":"2022","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.neurot.2024.e00446_bib199","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00401-018-1812-4","article-title":"The role of brain barriers in fluid movement in the CNS: is there a \u201cglymphatic\u201d system?","volume":"135","author":"Abbott","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2024.e00446_bib200","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1021\/acs.bioconjchem.8b00548","article-title":"Passive immunotherapies for central nervous system disorders: current delivery challenges and new approaches","volume":"29","author":"Kumar","year":"2018","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.neurot.2024.e00446_bib201","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1146\/annurev-pathol-051217-111018","article-title":"The glymphatic system in central nervous system health and disease: past, present, and future","volume":"13","author":"Plog","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.neurot.2024.e00446_bib202","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib203","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1111\/cts.13028","article-title":"Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease","volume":"14","author":"Hammon","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.neurot.2024.e00446_bib204","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/jnr.23423","article-title":"Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease)","volume":"92","author":"Katz","year":"2014","journal-title":"J\u00a0Neurosci Res"},{"key":"10.1016\/j.neurot.2024.e00446_bib205","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ymgme.2014.09.004","article-title":"Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis","volume":"114","author":"Vuillemenot","year":"2015","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib206","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cmet.2019.07.002","article-title":"Targeting pathogenic Lafora bodies in Lafora disease using an antibody-enzyme fusion","volume":"30","author":"Brewer","year":"2019","journal-title":"Cell Metabol"},{"key":"10.1016\/j.neurot.2024.e00446_bib207","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1021\/acs.molpharmaceut.9b00396","article-title":"Central nervous system delivery and biodistribution analysis of an antibody-enzyme fusion for the treatment of lafora disease","volume":"16","author":"Austin","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.neurot.2024.e00446_bib208","doi-asserted-by":"crossref","first-page":"107317","DOI":"10.1016\/j.eplepsyres.2024.107317","article-title":"Effect of intracerebroventricular administration of alglucosidase alfa in two mouse models of Lafora disease: relevance for clinical practice","volume":"200","author":"Zafra-Puerta","year":"2024","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurot.2024.e00446_bib209","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/cpt.18","article-title":"Targeted delivery of protein and gene medicines through the blood-brain barrier","volume":"97","author":"Pardridge","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.neurot.2024.e00446_bib210","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1210\/endo.135.5.7525251","article-title":"Insulin-like growth factors cross the blood-brain barrier","volume":"135","author":"Reinhardt","year":"1994","journal-title":"Endocrinology"},{"key":"10.1016\/j.neurot.2024.e00446_bib211","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0026-0495(98)90007-5","article-title":"Human blood-brain barrier insulin-like growth factor receptor","volume":"37","author":"Duffy","year":"1988","journal-title":"Metabolism"},{"key":"10.1016\/j.neurot.2024.e00446_bib212","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20211057","article-title":"Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme","volume":"219","author":"Arguello","year":"2022","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib213","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1016\/j.cell.2021.08.002","article-title":"Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic","volume":"184","author":"Logan","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.neurot.2024.e00446_bib214","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1124\/jpet.116.235952","article-title":"Reveglucosidase alfa (BMN 701), an IGF2-tagged rhAcid \u03b1-glucosidase, improves respiratory functional parameters in a murine model of Pompe disease","volume":"360","author":"Peng","year":"2017","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"key":"10.1016\/j.neurot.2024.e00446_bib215","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13023-017-0693-2","article-title":"A\u00a0study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease","volume":"12","author":"Byrne","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.neurot.2024.e00446_bib216","doi-asserted-by":"crossref","first-page":"eabj2658","DOI":"10.1126\/scitranslmed.abj2658","article-title":"Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease","volume":"14","author":"Jennings","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib217","series-title":"Presented at WORLDSymposium 2024; february 08","article-title":"Anti-human-TfR-GAA efficiently clears CNS and muscle glycogen in a translatable hTfR-KI\/Pompe mouse disease model","author":"van der Flier","year":"2024"},{"key":"10.1016\/j.neurot.2024.e00446_bib218","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00731489","article-title":"Treatment of Gaucher disease with an enzyme inhibitor","volume":"13","author":"Radin","year":"1996","journal-title":"Glycoconj J"},{"key":"10.1016\/j.neurot.2024.e00446_bib219","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/BF03195237","article-title":"Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases","volume":"48","author":"Jak\u00f3bkiewicz-Banecka","year":"2007","journal-title":"J\u00a0Appl Genet"},{"key":"10.1016\/j.neurot.2024.e00446_bib220","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/hmg\/ddp535","article-title":"Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease","volume":"19","author":"Douillard-Guilloux","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00446_bib221","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ana.23899","article-title":"Inhibiting glycogen synthesis prevents Lafora disease in a mouse model","volume":"74","author":"Pederson","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00446_bib222","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1093\/brain\/awab194","article-title":"Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease","volume":"144","author":"Ahonen","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2024.e00446_bib223","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s13311-023-01434-9","article-title":"Gys1 antisense therapy prevents disease-driving aggregates and epileptiform discharges in a lafora disease mouse model","volume":"20","author":"Donohue","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2024.e00446_bib224","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s13311-021-01040-7","article-title":"Targeting Gys1 with AAV-SaCas9 decreases pathogenic polyglucosan bodies and neuroinflammation in adult polyglucosan body and lafora disease mouse models","volume":"18","author":"Gumusgoz","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2024.e00446_bib225","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1093\/hmg\/ddn290","article-title":"Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II","volume":"17","author":"Douillard-Guilloux","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00446_bib226","doi-asserted-by":"crossref","first-page":"eadf1691","DOI":"10.1126\/scitranslmed.adf1691","article-title":"Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders","volume":"16","author":"Ullman","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib227","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000526317","article-title":"Gene therapy for inherited retinal disease: long-term durability of effect","volume":"66","author":"Leroy","year":"2023","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.neurot.2024.e00446_bib228","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib229","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1517\/14712598.2012.681463","article-title":"The advent of AAV9 expands applications for brain and spinal cord gene delivery","volume":"12","author":"Dayton","year":"2012","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.neurot.2024.e00446_bib230","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnmol.2015.00036","article-title":"Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice","volume":"8","author":"Tanguy","year":"2015","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.neurot.2024.e00446_bib231","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.omtm.2020.04.001","article-title":"Intra-CSF AAV9 and AAVrh10 administration in nonhuman primates: promising routes and vectors for which neurological diseases?","volume":"17","author":"Bey","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00446_bib232","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.exer.2010.08.011","article-title":"Transduction of the inner mouse retina using AAVrh8 and AAVrh10 via intravitreal injection","volume":"91","author":"Giove","year":"2010","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.neurot.2024.e00446_bib233","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/mt.2014.68","article-title":"Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10","volume":"22","author":"Yang","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00446_bib234","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/mt.2011.214","article-title":"Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice","volume":"20","author":"Qiu","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00446_bib235","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40478-017-0464-2","article-title":"Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease","volume":"5","author":"Hordeaux","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurot.2024.e00446_bib236","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1007\/s12035-017-0763-4","article-title":"A\u00a0neuron-specific gene therapy relieves motor deficits in Pompe disease mice","volume":"55","author":"Lee","year":"2018","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.neurot.2024.e00446_bib237","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.omtm.2019.01.006","article-title":"Intravenous injection of an AAV-PHP.B vector encoding human acid \u03b1-glucosidase rescues both muscle and CNS defects in murine Pompe disease","volume":"12","author":"Lim","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00446_bib238","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ymthe.2005.04.024","article-title":"Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II","volume":"12","author":"Franco","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00446_bib239","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/hum.2015.103","article-title":"Copackaged AAV9 vectors promote simultaneous immune tolerance and phenotypic correction of Pompe disease","volume":"27","author":"Doerfler","year":"2016","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00446_bib240","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1089\/hum.2008.010","article-title":"Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice","volume":"19","author":"Ziegler","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00446_bib241","doi-asserted-by":"crossref","first-page":"eaam6375","DOI":"10.1126\/scitranslmed.aam6375","article-title":"Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid \u03b1-glucosidase","volume":"9","author":"Puzzo","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib242","doi-asserted-by":"crossref","first-page":"103052","DOI":"10.1016\/j.ebiom.2020.103052","article-title":"Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defects","volume":"61","author":"Colella","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neurot.2024.e00446_bib243","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1016\/j.ymthe.2020.05.025","article-title":"Rescue of advanced Pompe disease in mice with hepatic expression of secretable acid \u03b1-glucosidase","volume":"28","author":"Cagin","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00446_bib244","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170199","article-title":"AAV-mediated delivery of secreted acid \u03b1-glucosidase with enhanced uptake corrects neuromuscular pathology in Pompe mice","volume":"8","author":"Meena","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.neurot.2024.e00446_bib245","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.ymthe.2024.05.032","article-title":"Gene therapy for Lafora disease in the Epm2a-\/- mouse model","volume":"32","author":"Zafra-Puerta","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00446_bib246","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac168","article-title":"Malin restoration as proof of concept for gene therapy for Lafora disease","volume":"4","author":"Varea","year":"2022","journal-title":"Brain Commun"},{"key":"10.1016\/j.neurot.2024.e00446_bib247","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1089\/hum.2016.099","article-title":"Systemic correction of murine glycogen storage disease type IV by an AAV-mediated gene therapy","volume":"28","author":"Yi","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurot.2024.e00446_bib248","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114554","article-title":"Alleviation of a polyglucosan storage disorder by enhancement of autophagic glycogen catabolism","volume":"13","author":"Kakhlon","year":"2021","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib249","first-page":"1","article-title":"Amylopectinosis of the fatal epilepsy Lafora disease resists autophagic glycogen catabolism","author":"Wu","year":"2024","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.neurot.2024.e00446_bib250","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1007\/s12035-015-9091-8","article-title":"Pharmacological interventions to ameliorate neuropathological symptoms in a mouse model of lafora disease","volume":"53","author":"Berthier","year":"2016","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.neurot.2024.e00446_bib251","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s13311-022-01304-w","article-title":"Early treatment with metformin improves neurological outcomes in lafora disease","volume":"20","author":"Burgos","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2024.e00446_bib252","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3390\/pharmaceutics14040833","article-title":"Ultrasound-mediated blood-brain barrier disruption for drug delivery: a systematic review of protocols, efficacy, and safety outcomes from preclinical and clinical studies","volume":"14","author":"Gandhi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neurot.2024.e00446_bib253","doi-asserted-by":"crossref","first-page":"114539","DOI":"10.1016\/j.addr.2022.114539","article-title":"Ultrasound-mediated blood-brain barrier opening: an effective drug delivery system for theranostics of brain diseases","volume":"190","author":"Wang","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.neurot.2024.e00446_bib254","doi-asserted-by":"crossref","first-page":"115323","DOI":"10.1016\/j.addr.2024.115323","article-title":"Recent advances of focused ultrasound induced blood-brain barrier opening for clinical applications of neurodegenerative diseases","volume":"209","author":"Zhao","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.neurot.2024.e00446_bib255","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11095-022-03185-2","article-title":"Focused ultrasound-mediated drug delivery in humans - a path towards translation in neurodegenerative diseases","volume":"39","author":"Wasielewska","year":"2022","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.neurot.2024.e00446_bib256","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000535621","article-title":"Focused ultrasound for treatment of movement disorders: a review of non-food and drug administration approved indications","volume":"102","author":"Cummins","year":"2024","journal-title":"Stereotact Funct Neurosurg"},{"key":"10.1016\/j.neurot.2024.e00446_bib257","article-title":"Long-term safety of repeated blood-brain barrier opening via focused ultrasound with microbubbles in non-human primates performing a cognitive task","volume":"10","author":"Downs","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2024.e00446_bib258","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1038\/s41467-018-04529-6","article-title":"Blood-brain barrier opening in Alzheimer\u2019s disease using MR-guided focused ultrasound","volume":"9","author":"Lipsman","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2024.e00446_bib259","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41467-021-21022-9","article-title":"Blood-brain barrier opening with focused ultrasound in Parkinson\u2019s disease dementia","volume":"12","author":"Gasca-Salas","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2024.e00446_bib260","first-page":"275","article-title":"Focused ultrasound-mediated blood-brain barrier opening in Alzheimer\u2019s disease:\u00a0long-term safety, imaging, and cognitive outcomes","volume":"139","author":"Rezai","year":"2023","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.neurot.2024.e00446_bib261","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.7150\/thno.24512","article-title":"MRI and histological evaluation of pulsed focused ultrasound and microbubbles treatment effects in the brain","volume":"8","author":"Kovacs","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.neurot.2024.e00446_bib262","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.2174\/1381612826666200224112534","article-title":"Drug development for central nervous system diseases using in vitro blood-brain barrier models and drug repositioning","volume":"26","author":"Morofuji","year":"2020","journal-title":"Curr Pharmaceut Des"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924001338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924001338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:09:23Z","timestamp":1762560563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747924001338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":262,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1878747924001338"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00446","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurological glycogen storage diseases and emerging therapeutics","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00446"}}